2023 Report Shows 2,770 Cases of Arboviral Disease Across 48 States and D.C.

In 2023, nearly 2,800 arboviral disease cases were reported across most U.S. states, primarily caused by West Nile Virus, with serious health implications. Learn more about the latest CDC findings.
In 2023, a total of 2,770 human cases of arboviral diseases were documented across 48 U.S. states and the District of Columbia, according to a report published in the June 12 issue of the Morbidity and Mortality Weekly Report by the CDC. The majority of these cases involved West Nile Virus (WNV), which constituted approximately 95% of the total, with 2,628 confirmed cases. These infections often led to hospitalizations, with 2,022 reported in total, and 208 deaths. Most cases (about 91%) began between July and September, aligning with peak mosquito activity season. Notably, three cases of WNV were linked to organ transplants from two donors, highlighting the importance of vigilance in transplant procedures. The second most common disease was Powassan virus, with 49 cases, showing an increase from the previous year’s record. Among children, La Crosse virus remained a significant cause of neuroinvasive arboviral disease. Health experts continue advising clinicians to consider arboviral testing in patients presenting with febrile or neurological symptoms, especially during tick and mosquito seasons, and among transplant or blood transfusion recipients.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Testosterone Gel Shows No Additional Benefits for Women Recovering from Hip Fractures, Study Finds
A recent clinical trial found that testosterone gel does not significantly improve overall recovery in women after hip fractures, highlighting the importance of exercise in rehabilitation efforts.
New Hope in Lymphoma Treatment: Terbium-161 Radioimmunotherapy
Researchers at PSI have developed a targeted radioimmunotherapy using terbium-161 to effectively combat lymphoma, offering new hope for precise and effective treatment options.
Innovative Treatment Shows Promise for Advanced Pulmonary Arterial Hypertension Patients
New research reveals that sotatercept, initially approved for mild PAH, significantly reduces mortality and hospitalizations in advanced cases, offering new hope for patients with this severe lung condition.